MedTrace Logo

An Integrative-"Omics" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China

NCT03076580 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2018-04-19

No results posted yet for this study

Summary

This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.

Conditions

  • Dilated Cardiomyopathy
  • Hypertrophic Cardiomyopathy
  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Left Ventricular Non-compaction
  • Restrictive Cardiomyopathy

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Beijing Anzhen Hospital

    collaborator OTHER

  • Beijing Institute of Heart, Lung and Blood Vessel Diseases

    lead OTHER

Principal Investigators

  • Jie Du, PhD · Beijing Anzhen Hospital affiliated to Capital Medical University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2018-07-01
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076580 on ClinicalTrials.gov